Epidemiology of bronchopulmonary dysplasia.
First described more than 40 years ago, bronchopulmonary dysplasia (BPD) remains one of the most serious and vexing challenges in the care of very preterm infants. Affecting approximately one-quarter of infants born <1500g birth weight, BPD is associated with prolonged neonatal intensive care unit hospitalization, greater risk of neonatal and post-neonatal mortality and a host of associated medical and neurodevelopmental sequelae. This seminar focuses on the epidemiology and definition of BPD as well as the current evidence pertaining to a number of potential preventive treatments for BPD: non-invasive respiratory support technologies, inhaled nitric oxide, vitamin A, and caffeine.
Van Marter
Linda J
LJ
Children's Hospital and Brigham & Women's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, USA. linda.vanmarter@childrens.harvard.edu
D001997:Bronchopulmonary Dysplasia / Q000453:epidemiology* / Q000517:prevention & control / Q000628:therapy; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D007234:Infant, Premature / Q000502:physiology*; D012307:Risk Factors